Skip to content
← All treatment topics

TREATMENT READING

Peripheral T-Cell Non-Hodgkin Lymphoma

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

30 sections
  1. Late Effects of Treatment of Peripheral T-Cell Non-Hodgkin Lymphoma
  2. Treatment of Anaplastic Large Cell Lymphoma
  3. Treatment Options for Anaplastic Large Cell Lymphoma
  4. Breast Implant–Associated Anaplastic Large Cell Lymphoma
  5. Treatment of Nodal Lymphomas of T Follicular Helper Cell Origin
  6. Treatment Options for Nodal Lymphomas of T Follicular Helper Cell Origin
  7. Treatment of Peripheral T-Cell Lymphoma, Not Otherwise Specified
  8. Prognosis
  9. Treatment Options for Peripheral T-Cell Lymphoma, Not Otherwise Specified
  10. Treatment of Extranodal Natural Killer/T-Cell Lymphoma
  11. Treatment Options for Extranodal Natural Killer/T-Cell Lymphoma
  12. Treatment of Enteropathy-Associated and Monomorphic Epitheliotropic Intestinal T-Cell Lymphomas
  13. Treatment Options for Enteropathy-Associated and Monomorphic Epitheliotropic Intestinal T-Cell Lymphomas
  14. Treatment of Indolent T-Cell Lymphoma of the Gastrointestinal Tract
  15. Treatment Options for Indolent T-Cell Lymphoma of the Gastrointestinal Tract
  16. Treatment of Hepatosplenic T-Cell Lymphoma
  17. Treatment Options for Hepatosplenic T-Cell Lymphoma
  18. Treatment of Adult T-Cell Leukemia/Lymphoma
  19. Treatment Options for Adult T-Cell Leukemia/Lymphoma
  20. Biological and targeted therapies
  21. Mogamulizumab
  22. Brentuximab vedotin
  23. Lenalidomide
  24. Valemetostat
  25. Zidovudine and interferon alfa
  26. Cytotoxic chemotherapy and allogeneic SCT
  27. Treatment of T-Cell Prolymphocytic Leukemia
  28. Treatment Options for T-Cell Prolymphocytic Leukemia
  29. Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
  30. Treatment Options for Relapsed or Refractory Peripheral T-Cell Lymphoma

Health professional

Late Effects of Treatment of Peripheral T-Cell Non-Hodgkin Lymphoma

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Late effects of treatment of non-Hodgkin lymphoma (NHL) have been observed. Impaired fertility may occur after exposure to alkylating agents.[1] For as many as three decades after diagnosis, patients are at a significantly elevated risk of developing second primary cancers, especially the following:[2-5]

Sources: 1 · 2 · 5

Lung cancer.

Brain cancer.

Kidney cancer.

Bladder cancer.

Melanoma.

Hodgkin lymphoma.

Acute nonlymphocytic leukemia.

Left ventricular dysfunction was a significant late effect in long-term survivors of high-grade NHL who received more than 200 mg/m² of doxorubicin.[1,6]

Sources: 1 · 6

Myelodysplastic syndrome and acute myelogenous leukemia are late complications of myeloablative therapy with autologous bone marrow or peripheral blood stem cell support, as well as conventional chemotherapy-containing alkylating agents.[3,7-14] Most of these patients show clonal hematopoiesis even before the transplant, suggesting that the hematologic injury usually occurs during induction or reinduction chemotherapy.[9,15,16] A series of 605 patients who received autologous bone marrow transplant (BMT) with cyclophosphamide and total-body radiation therapy (as conditioning) were followed for a median of 10 years. The incidence of a second malignancy was 21%, and 10% of those malignancies were solid tumors.[17]

Sources: 3 · 7 · 14 · 9 · 15 · 16 · 17

A study of young women who received autologous BMT reported successful pregnancies with children born free of congenital abnormalities.[18] Late-occurring venous thromboembolism can occur after allogeneic or autologous BMT.[19]

Sources: 18 · 19

Some patients have osteopenia or osteoporosis at the start of therapy; bone density may worsen after therapy for lymphoma.[20]

Sources: 20

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional

Treatment of Anaplastic Large Cell Lymphoma

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Anaplastic large cell lymphoma (ALCL) is a peripheral T-cell lymphoma associated with the CD30 antigen. The translocation of chromosomes 2 and 5 creates a unique fusion protein with a nucleophosmin–anaplastic lymphoma kinase (ALK).[1,2] Patients whose lymphomas express ALK by immunohistochemistry are usually younger and may have systemic symptoms, extranodal disease, and advanced-stage disease. However, they have a more favorable survival rate than patients with ALK-negative disease.[3,4] ALK-negative ALCL has been further characterized by DUSP22 chromosomal rearrangements and the presence of TP63 pathogenic variants. While DUSP22 rearrangements are associated with improved prognosis, TP63 pathogenic variants are associated with poorer outcomes.[5]

Sources: 1 · 2 · 3 · 4 · 5

Health professional · Treatment of Anaplastic Large Cell Lymphoma

Treatment Options for Anaplastic Large Cell Lymphoma

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

A prospective randomized trial included 452 patients with CD30-positive T-cell lymphoma (CD30 expression >10%). Of these patients, 70% had ALCL (22% with ALK-positive disease and 48% with ALK-negative disease). The trial compared the previously used standard regimen, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), with brentuximab vedotin (an anti-CD30 monoclonal antibody conjugated to a cytotoxic agent) combined with cyclophosphamide, doxorubicin, and prednisone (A+CHP regimen).[6]

Sources: 6

A prospective randomized trial included 452 patients with CD30-positive T-cell lymphoma (CD30 expression >10%). Of these patients, 70% had ALCL (22% with ALK-positive disease and 48% with ALK-negative disease). The trial compared the previously used standard regimen, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), with brentuximab vedotin (an anti-CD30 monoclonal antibody conjugated to a cytotoxic agent) combined with cyclophosphamide, doxorubicin, and prednisone (A+CHP regimen).[6]

With a median follow-up of 47.6 months, the 5-year overall survival (OS) rates were 70.1% (95% confidence interval [CI], 63.3%–75.9%) for patients who received A+CHP and 61.0% (95% CI, 54.0%–67.3%) for patients who received CHOP (hazard ratio [HR], 0.72; 95% CI, 0.53–0.99).[7][Level of evidence A1]

Sources: 7 · Level of evidence A1

The 5-year progression-free survival (PFS) rates were 51.4% (95% CI, 42.8%–59.4%) for patients who received A+CHP and 43.0% (95% CI, 35.8%–50.0%) for patients who received CHOP (HR, 0.70; 95% CI, 0.53–0.91).

This established A+CHP as a new option for patients with ALCL or other CD30-positive T-cell lymphomas, such as angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified.

For patients with relapsed disease, anecdotal responses have been reported for brentuximab vedotin,[8-11] belinostat,[12] romidepsin,[13] and pralatrexate.[14][Level of evidence C3]

Sources: 8 · 11 · 12 · 13 · 14 · Level of evidence C3

In a phase II study (NCT00866047), 66% of 58 patients attained a complete response with brentuximab vedotin.[11]

Sources: NCT00866047 · 11

In a phase II study (NCT00866047), 66% of 58 patients attained a complete response with brentuximab vedotin.[11]

At a median follow-up of 58 months, the 5-year PFS rate was 57% (95% CI, 41%–74%), and the 5-year OS rate was 79% (95% CI, 65%–92%). Of the patients achieving a complete response, 42% underwent hematopoietic stem cell transplant (SCT).[11][Level of evidence C3]

Sources: 11 · Level of evidence C3

In a retrospective review, 39 patients with relapsed disease had a 3-year PFS rate of 50% after autologous or allogeneic SCT.[15][Level of evidence C2]

Sources: 15 · Level of evidence C2

A retrospective review of 84 patients with ALK-negative ALCL suggested a survival benefit with autologous SCT. This hypothesis requires confirmation in a randomized prospective trial.[16][Level of evidence C3]

Sources: 16 · Level of evidence C3

A retrospective study included 182 patients with relapsed or refractory ALCL (23% ALK-positive, 21% ALK-negative, and 56% ALK-unknown) who underwent allogeneic SCT.[17]

Sources: 17

A retrospective study included 182 patients with relapsed or refractory ALCL (23% ALK-positive, 21% ALK-negative, and 56% ALK-unknown) who underwent allogeneic SCT.[17]

The 5-year PFS rate was 41% (95% CI, 34%–49%), and the 5-year OS rate was 41% (95% CI, 49%–64%).[17][Level of evidence C3]

Sources: 17 · Level of evidence C3

On multivariate analysis, African American race (HR, 2.7; 95% CI, 1.6–4.8; P < .001) and refractory disease at time of allogeneic SCT (HR, 3.2; 95% CI, 1.6–6.2; P < .001) were predictive factors for inferior OS.

Despite ALK positivity being a favorable prognostic factor, outcomes after allogeneic SCT in this study did not vary significantly according to ALK status.

ALCL in children is usually characterized by systemic and cutaneous disease and has high response rates and good OS with doxorubicin-based combination chemotherapy.[18] The ALK inhibitor crizotinib has been combined with chemotherapy for previously untreated pediatric patients, and crizotinib has been used to control disease in multiply relapsed pediatric patients.[19,20] Crizotinib is associated with a high risk (around 25%) of thromboembolism, especially pulmonary embolism, and prophylaxis is recommended. There are no reports supporting the use of crizotinib in adults.

Sources: 18 · 19 · 20

Health professional · Treatment of Anaplastic Large Cell Lymphoma

Breast Implant–Associated Anaplastic Large Cell Lymphoma

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Patients with breast implant–associated ALCL may do well without chemotherapy after capsulectomy and implant removal if the disease is confined to the fibrous capsule, and no associated mass or lymphadenopathy is present.[21-24] Most patients with breast implant–associated ALCL have a characteristic deletion at 20Q13.13 that may help to diagnostically distinguish it from cutaneous or systemic ALCL.[25]

Sources: 21 · 24 · 25

Primary cutaneous ALCL is a distinct entity that is typically ALK-negative and has a very indolent/low-grade clinical course. Breast implant–associated ALCL almost always occurs with implants that have a textured surface (so-called macrotextured implants) that helps adhere to the breast. Warnings, suspensions, and bans of macrotextured implants have occurred worldwide. The risk of breast implant–associated ALCL is approximately 1 in 12,000 people, but this risk may rise with further follow-up.[26]

Sources: 26

Health professional

Treatment of Nodal Lymphomas of T Follicular Helper Cell Origin

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

The 2016 World Health Organization (WHO) classification recognized nodal lymphomas of T follicular helper (TFH) cell origin as a distinct subset of peripheral T-cell lymphoma (PTCL). Unified by a CD4+ TFH cell origin, this subset includes:[1]

Sources: 1

Angioimmunoblastic T-cell lymphoma (AITL or ATCL).

Follicular peripheral T-cell lymphoma (F-PTCL).

Nodal peripheral T-cell lymphoma with follicular helper phenotype (nodal PTCL with TFH phenotype).

AITL is the most common of these entities and is the second-most common subtype of PTCL.[2-5] Patients often present with profound lymphadenopathy, fever, night sweats, weight loss, skin rash, a positive Coombs test, and polyclonal hypergammaglobulinemia.[6] Opportunistic infections are frequent because of an underlying immune deficiency. B-cell Epstein-Barr virus genomes are detected in most affected patients.[7] For more information about weight loss, see Nutrition in Cancer Care and for more information about skin rash, see Pruritus.

Sources: 2 · 5 · 6 · 7 · Nutrition in Cancer Care · Pruritus

The remaining subtypes of nodal lymphomas of TFH cell origin, including F-PTCL and nodal PTCL with TFH phenotype, are derived from the same cell of origin. However, unlike AITL, these subtypes are not associated with hypervascularity on nodal biopsy and often lack the hyperinflammatory symptoms characteristic of AITL.[1]

Sources: 1

Health professional · Treatment of Nodal Lymphomas of T Follicular Helper Cell Origin

Treatment Options for Nodal Lymphomas of T Follicular Helper Cell Origin

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Doxorubicin-based combination chemotherapy, such as the CHO(E)P regimen (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone), is commonly used for patients with AITL and other nodal lymphomas of TFH cell origin.[2,5] For CD30-positive cases, brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone is the proposed standard of care.[8][Level of evidence C3] Patients with AITL were included in a clinical trial involving mostly patients with anaplastic large cell lymphoma. A benefit for this smaller AITL subgroup cannot be established.[8,9][Level of evidence C3] For more information, see the Treatment of Anaplastic Large Cell Lymphoma section.

Sources: 2 · 5 · 8 · Level of evidence C3 · 8 · 9 · Level of evidence C3 · Treatment of Anaplastic Large Cell Lymphoma

The International Peripheral T-Cell Lymphoma Project involving 22 international centers identified 243 patients with AITL. The 5-year overall survival rate was 33%, and the failure-free survival rate was 18%.[10] Myeloablative chemotherapy and radiation therapy with autologous or allogeneic peripheral stem cell support has been described in anecdotal reports.[11-16][Level of evidence C3] Anecdotal responses have been reported for patients who received cyclosporine,[17] pralatrexate,[18] bendamustine,[19] belinostat,[20] the histone deacetylase inhibitor romidepsin, hypomethylating agents (HMAs),[21,22] and brentuximab vedotin (even if there is little or no CD30 expression on the lymphoma).[23,24][Level of evidence C3] Occasional spontaneous remissions and protracted responses to steroids only have been reported. Given increased frequency of pathogenic variants in genes that regulate epigenetic modification—such as TET2, IDH2, and DNMT3A—there is increased interest in therapies targeting these aberrations with HMAs and histone deacetylase inhibitors with anecdotal reports of improved efficacy compared with other subsets of PTCL.[21,22,25][Level of evidence C3] Further studies are needed to better characterize the efficacy of this approach.[21,22,25]

Sources: 10 · 11 · 16 · Level of evidence C3 · 17 · 18 · 19 · 20 · 21 · 22 · 23 · 24 · Level of evidence C3 · 21 · 22 · 25 · Level of evidence C3 · 21 · 22 · 25

Health professional

Treatment of Peripheral T-Cell Lymphoma, Not Otherwise Specified

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Patients with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) have diffuse large cell or diffuse mixed lymphoma that expresses a cell surface phenotype of a postthymic (or peripheral) T-cell expressing either CD4 or, less often, CD8.[1] PTCL-NOS encompasses a group of heterogeneous nodal T-cell lymphomas that will require future delineation.[2,3] Gene expression profiling studies have identified two distinct subtypes of PTCL-NOS based on the transcription factors GATA3 and TBX21. Early investigation and anecdotal reports suggest these subtypes may carry important prognostic implications and could predict response to certain therapies.[4] Additional studies are needed for further characterization of their clinical relevance.

Sources: 1 · 2 · 3 · 4

Health professional · Treatment of Peripheral T-Cell Lymphoma, Not Otherwise Specified

Prognosis

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Most investigators report worse response and survival rates for patients with PTCL-NOS than for patients with comparably staged B-cell aggressive lymphomas.[3,5] Most patients present with multiple adverse prognostic factors (i.e., older age, stage IV, multiple extranodal sites, and elevated lactate dehydrogenase), and these patients have low (<20%) failure-free survival and overall survival (OS) rates at 5 years.[3,5] As with other lymphomas (e.g., diffuse large B-cell lymphoma [DLBCL] or follicular lymphoma), event-free survival (EFS) at 24 months predicts a 5-year OS rate of 78%.[6]

Sources: 3 · 5 · 3 · 5 · 6

Health professional · Treatment of Peripheral T-Cell Lymphoma, Not Otherwise Specified

Treatment Options for Peripheral T-Cell Lymphoma, Not Otherwise Specified

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Therapy involves doxorubicin-based combination chemotherapy such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHO(E)P (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone). Doses are the same as those used for DLBCL.[7] For CD30-positive cases, brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone is the proposed standard of care.[8][Level of evidence C3] Patients with PTCL-NOS were included in the clinical trial involving mostly patients with anaplastic large cell lymphoma. A benefit for this smaller PTCL-NOS subgroup cannot be established.[8,9][Level of evidence C3] For more information, see the Treatment of Anaplastic Large Cell Lymphoma section.

Sources: 7 · 8 · Level of evidence C3 · 8 · 9 · Level of evidence C3 · Treatment of Anaplastic Large Cell Lymphoma

For patients with early-stage disease, anecdotal retrospective series disagree on the value of consolidative radiation therapy after combination chemotherapy.[10][Level of evidence C3] Consolidation therapy using high-dose chemotherapy with autologous or allogeneic hematopoietic stem cell transplant (SCT) has been given to patients with advanced-stage PTCL after induction therapy in multiple phase II or retrospective trials. Evidence for this approach is anecdotal.[11-18][Level of evidence C3]

Sources: 10 · Level of evidence C3 · 11 · 18 · Level of evidence C3

Evidence (CHOP, CHO[E]P, or other options for relapsing disease):

A randomized prospective trial included 104 patients younger than 61 years with stage II, III, or IV PTCL (excluding ALK-positive anaplastic large cell lymphoma). Patients received either autologous SCT or allogeneic SCT as consolidation therapy after induction with CHO(E)P followed by DHAP (dexamethasone, cytarabine, and cisplatin).[19][Level of evidence C3]

Sources: 19 · Level of evidence C3

A randomized prospective trial included 104 patients younger than 61 years with stage II, III, or IV PTCL (excluding ALK-positive anaplastic large cell lymphoma). Patients received either autologous SCT or allogeneic SCT as consolidation therapy after induction with CHO(E)P followed by DHAP (dexamethasone, cytarabine, and cisplatin).[19][Level of evidence C3]

With a median follow-up of 42 months, the 3-year EFS rate was 43% for patients who received allogeneic SCT and 38% for patients who received autologous SCT.

The 3-year OS rate was 57% for patients who received allogeneic SCT and 70% for patients who received autologous SCT (P = nonsignificant).

None of the 21 responding patients who proceeded to allogeneic SCT relapsed, and 36% of patients who proceeded to autologous SCT relapsed.

Eight of 26 patients (31%) who received allogeneic SCT died of graft-versus-host disease, and none of the 41 patients who received autologous SCT died of toxicity.

The benefit of graft-versus-lymphoma effect was negated by increased transplant-related mortality.

In a prospective trial of 109 evaluable patients with relapsing disease, treatment with pralatrexate resulted in a 30% response rate and a median 10-month duration of response.[20,21][Level of evidence C3]

Sources: 20 · 21 · Level of evidence C3

Similar response rates were seen in 130 evaluable patients with relapsing disease who received romidepsin in a prospective trial.[21][Level of evidence C3]

Sources: 21 · Level of evidence C3

Anecdotal responses have been seen with a combination of pralatrexate and romidepsin,[22] single-agent bendamustine,[23] belinostat,[24] and brentuximab vedotin (even if there is little or no CD30 expression on the lymphoma).[25][Level of evidence C3]Incorporation of these new agents with CHOP chemotherapy is under clinical evaluation.[3,8]

Sources: 22 · 23 · 24 · 25 · Level of evidence C3 · 3 · 8

Health professional

Treatment of Extranodal Natural Killer/T-Cell Lymphoma

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Extranodal natural killer (NK)/T-cell lymphoma, nasal type, is an aggressive lymphoma marked by extensive necrosis and angioinvasion, most often presenting in extranodal sites, in particular the nasal or paranasal sinus region.[1] Other extranodal sites include the palate, trachea, skin, and gastrointestinal tract. Hemophagocytic syndrome may also occur; historically, these tumors were considered part of lethal midline granuloma.[2] Tumor cells are typically NK cells with immunophenotyping showing CD3 and CD56 expression. In nearly all cases, Epstein-Barr virus (EBV) is detectable in the tumor cells. Aggressive NK cell leukemia (ANKL) is a separate but related diagnosis, which was previously recognized as a subset of large granular lymphocyte (LGL) leukemia, and is characterized by mature NK cell neoplastic involvement of the blood or marrow involvement with a particularly aggressive course and poor prognosis.[3] A benign NK-cell enteropathy (EBV negative) on endoscopic biopsy can be distinguished from NK/T-cell lymphoma.[3] Extranodal NK-cell lymphoma (ENKL), nasal type is rare in Western countries and more commonly seen in Asia, where it represents 3% to 8% of all lymphoma cases. Most cases present with nasal involvement and localized disease. Both extranasal and advanced-stage (stages III–IV) disease are associated with poor prognosis.[4,5]

Sources: 1 · 2 · 3 · 3 · 4 · 5

Health professional · Treatment of Extranodal Natural Killer/T-Cell Lymphoma

Treatment Options for Extranodal Natural Killer/T-Cell Lymphoma

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

The management of localized ENKL with nasal involvement involves combined modality therapy with chemotherapy and radiation therapy for those fit for chemotherapy or radiation therapy alone for those unfit for chemotherapy. The management of nonlocalized nasal ENKL and all cases of extranasal ENKL involves combination chemotherapy with or without radiation therapy.[6] Because ENKL frequently expresses P-glycoprotein which confers multidrug resistance and reduces the efficacy of traditional anthracycline-based regimens, asparaginase is typically incorporated into the chemotherapy regimens.[7,8] Various asparaginase-based combination chemotherapy regimens have been used.

Sources: 6 · 7 · 8

Evidence (asparaginase-based combination chemotherapy):

A phase II study included 28 patients with newly diagnosed stage IV or relapsed or refractory ENKL. Patients received steroids, methotrexate, ifosfamide, [L-]asparaginase, and etoposide (SMILE).[9] Despite no head-to-head studies, this regimen is used more often in clinical practice, in patients with advanced-stage disease, or in combination with radiation therapy for patients with localized disease. Other asparaginase-based regimens which have been studied include gemcitabine, oxaliplatin, and pegaspargase (P-GEMOX);[10] gemcitabine, etoposide, pegaspargase, and dexamethasone (GELAD);[11] and dexamethasone, cisplatin, gemcitabine, and pegaspargase (DDGP).[12]For patients who may not tolerate or who have reactions to asparaginase, a nonasparaginase regimen may be given with concurrent radiation therapy.[13][Level of evidence C3]

Sources: 9 · 10 · 11 · 12 · 13 · Level of evidence C3

A phase II study included 28 patients with newly diagnosed stage IV or relapsed or refractory ENKL. Patients received steroids, methotrexate, ifosfamide, [L-]asparaginase, and etoposide (SMILE).[9] Despite no head-to-head studies, this regimen is used more often in clinical practice, in patients with advanced-stage disease, or in combination with radiation therapy for patients with localized disease. Other asparaginase-based regimens which have been studied include gemcitabine, oxaliplatin, and pegaspargase (P-GEMOX);[10] gemcitabine, etoposide, pegaspargase, and dexamethasone (GELAD);[11] and dexamethasone, cisplatin, gemcitabine, and pegaspargase (DDGP).[12]For patients who may not tolerate or who have reactions to asparaginase, a nonasparaginase regimen may be given with concurrent radiation therapy.[13][Level of evidence C3]

The overall response rate after two cycles was 79% (95% confidence interval [CI], 65%–89%), and the complete response rate was 45%. The 1-year overall survival (OS) rate was 55% (95% CI, 38%–69%).

Grade 4 neutropenia was observed in 92% of patients, and grade 3 or 4 infections were seen in 61% of patients.[9]

Sources: 9

A modification to the SMILE regimen (mSMILE) incorporating pegylated asparaginase has demonstrated reduced toxicity.[10]

Sources: 10

A retrospective study (NCT02733458) included 35 patients with newly diagnosed stage III to IV, relapsed, or refractory ENKL. Patients received P-GEMOX.[10]

Sources: NCT02733458 · 10

A retrospective study (NCT02733458) included 35 patients with newly diagnosed stage III to IV, relapsed, or refractory ENKL. Patients received P-GEMOX.[10]

The overall response rate was 80.0%, and the complete response rate was 51.4%. The 3-year progression-free survival (PFS) rate was 38.6%, and the 3-year OS rate was 64.7%.[10][Level of evidence C3]

Sources: 10 · Level of evidence C3

A prospective multicenter study (NCT02733458) included 52 patients with newly diagnosed stage IE/IIE ENKL who received two cycles of GELAD followed by intensity-modulated radiotherapy (50–56 Gy in 25–58 fractions) and two additional courses of GELAD.[11]

Sources: NCT02733458 · 11

A prospective multicenter study (NCT02733458) included 52 patients with newly diagnosed stage IE/IIE ENKL who received two cycles of GELAD followed by intensity-modulated radiotherapy (50–56 Gy in 25–58 fractions) and two additional courses of GELAD.[11]

With a median follow-up of 32 months, the estimated 4-year OS rate was 94.2% (95% CI, 83.2%–93.1%), and the 4-year PFS rate was 90.4% (95% CI, 78.4%–95.9%).[11][Level of evidence C3]

Sources: 11 · Level of evidence C3

The overall response rate was 94.2%, and the complete response rate was 92.3%.

A retrospective study included 80 patients with newly diagnosed (n = 48), refractory (n = 23), or first-relapse (n = 9) ENKL. Patients received DDGP.[12]

Sources: 12

A retrospective study included 80 patients with newly diagnosed (n = 48), refractory (n = 23), or first-relapse (n = 9) ENKL. Patients received DDGP.[12]

The overall response rate was 91.3% (95% CI, 85.0%–96.3%), and the complete response rate was 60.0% (95% CI, 48.8%–71.3%). The 2-year PFS rate was 81.4% (95% CI, 76.3%–86.5%), and the 2-year OS rate was 87.1% (95% CI, 83.4%–91.4%).[12][Level of evidence C3]

Sources: 12 · Level of evidence C3

A phase I/II study of 27 patients with newly diagnosed stage IE or contiguous IIE disease studied the nonasparaginase-based regimen DeVIC (dexamethasone, etoposide, ifosfamide, and carboplatin). Patients received three cycles of DeVIC at the recommended phase II dosing and concurrent radiotherapy dosed at 50 Gy.[13]

Sources: 13

A phase I/II study of 27 patients with newly diagnosed stage IE or contiguous IIE disease studied the nonasparaginase-based regimen DeVIC (dexamethasone, etoposide, ifosfamide, and carboplatin). Patients received three cycles of DeVIC at the recommended phase II dosing and concurrent radiotherapy dosed at 50 Gy.[13]

With a median follow-up of 32 months, the 2-year OS rate was 78% (95% CI, 57%–89%). The overall response rate was 81%, and the complete response rate was 77%.[13][Level of evidence C3]

Sources: 13 · Level of evidence C3

The most common grade 3 or higher nonhematologic toxicity was mucositis related to radiation, which occurred in 30% of patients.

Radiation therapy is an essential component of treatment for localized ENKL, nasal type, whether given as a monotherapy or as part of combined modality therapy.

Evidence (radiation therapy with or without chemotherapy):

A retrospective review included 1,273 patients with early-stage disease. Patients were stratified into a low-risk group and high-risk group using stage, age, lactate dehydrogenase level, performance status, and primary tumor invasion.

A retrospective review included 1,273 patients with early-stage disease. Patients were stratified into a low-risk group and high-risk group using stage, age, lactate dehydrogenase level, performance status, and primary tumor invasion.

Low-risk patients fared best with radiation therapy alone,[14] while high-risk patients fared best with a strategy of radiation therapy combined with chemotherapy.[15-17][Level of evidence C3]

Sources: 14 · 15 · 17 · Level of evidence C3

A retrospective review included 303 previously untreated patients from an international consortium who received nonanthracycline chemotherapy.[18]

Sources: 18

A retrospective review included 303 previously untreated patients from an international consortium who received nonanthracycline chemotherapy.[18]

The OS rates were identical (72%−74% at 5 years) for patients with early-stage disease who received either concurrent chemotherapy and radiation therapy or chemotherapy followed by radiation therapy.[18][Level of evidence C3]

Sources: 18 · Level of evidence C3

Higher doses of radiation therapy administered at more than 50 Gy are associated with improved outcomes according to anecdotal reports.[17] The highly aggressive course, with poor response and short survival with standard therapies, especially for patients with advanced-stage disease or extranasal presentation, has led some investigators to recommend autologous or allogeneic peripheral stem cell transplant consolidation.[19-24][Level of evidence C3]

Sources: 17 · 19 · 24 · Level of evidence C3

For patients with relapsed or refractory disease, therapies targeting programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) have demonstrated promising results.

Evidence (immunotherapy):

In a phase II trial, the anti–PD-L1 antibody avelumab was given to 21 patients with relapsed or refractory disease.[25]

Sources: 25

In a phase II trial, the anti–PD-L1 antibody avelumab was given to 21 patients with relapsed or refractory disease.[25]

The complete response rate was 24%, and the overall response rate was 38%. The responses correlated with tumor PD-L1 expression.[25][Level of evidence C3]

Sources: 25 · Level of evidence C3

Treatment with pembrolizumab, an anti–PD-1 antibody, resulted in similar responses in patients with relapsed or refractory disease.[26][Level of evidence C3]

Sources: 26 · Level of evidence C3

A single-arm multicenter phase II study (GEMSTONE-201 [NCT03595657]) included 80 patients with relapsed or refractory ENKL. Patients received the anti–PD-L1 monoclonal antibody sugemalimab.

Sources: GEMSTONE-201

A single-arm multicenter phase II study (GEMSTONE-201 [NCT03595657]) included 80 patients with relapsed or refractory ENKL. Patients received the anti–PD-L1 monoclonal antibody sugemalimab.

The objective response rate was 44.9% (95% CI, 33.6%–56.6%), and the complete response rate was 35.9%. The 12-month duration of response rate was 82.5% (95% CI, 62.0%–92.6%).[27][Level of evidence B3]

Sources: 27 · Level of evidence B3

Health professional

Treatment of Enteropathy-Associated and Monomorphic Epitheliotropic Intestinal T-Cell Lymphomas

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Enteropathy-associated T-cell lymphoma (EATL) and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) are rare subsets of peripheral T-cell lymphoma (PTCL) which together account for less than 5% of PTCL. EATL (sometimes referred to as type 1 EATL) is a complication of celiac disease and is more common in Europe. MEITL (sometimes referred to as type 2 EATL) is not associated with celiac disease and is more common in Asia. SETD2 pathogenic variants and, to a lesser extent, STAT5B pathogenic variants are seen in most cases of EATL and MEITL.[1,2] Because a gluten-free diet prevents the development of lymphoma in patients with celiac disease, patients diagnosed in childhood rarely develop EATL. The diagnosis of celiac disease is usually made by finding villous atrophy in the resected intestine. Surgery is often required for diagnosis and to avoid perforation during therapy.[3]

Sources: 1 · 2 · 3

Health professional · Treatment of Enteropathy-Associated and Monomorphic Epitheliotropic Intestinal T-Cell Lymphomas

Treatment Options for Enteropathy-Associated and Monomorphic Epitheliotropic Intestinal T-Cell Lymphomas

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Recommended management includes CHO(E)P (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone), but relapse is common and outcomes are generally poor.[4-6] Complications of treatment include gastrointestinal bleeding, small bowel perforation, and enterocolic fistulae. Patients often require parenteral nutrition. For more information on parenteral nutrition, see Nutrition in Cancer Care. Multifocal intestinal perforations and visceral abdominal involvement are seen at the time of relapse. Consolidation with either high-dose chemotherapy with autologous stem cell rescue or allogeneic stem cell transplant is often used in first or later remission.[4,7,8][Level of evidence C3] Evidence for this approach is anecdotal.

Sources: 4 · 6 · Nutrition in Cancer Care · 4 · 7 · 8 · Level of evidence C3

Health professional

Treatment of Indolent T-Cell Lymphoma of the Gastrointestinal Tract

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

In contrast to the more aggressive forms of T-cell lymphoma with intestinal involvement, indolent T-cell lymphoma of the gastrointestinal tract (iTCL-GI) often presents more indolently. iTCL-GI can be difficult to distinguish from inflammatory bowel disease or other autoimmune disorders with gastrointestinal involvement.[1,2]

Sources: 1 · 2

iTCL-GI is often diagnosed when multiple biopsies from different sites show matching clones by T-cell receptor gene rearrangement testing. While the immunophenotype can vary (iTCL-GI is frequently CD4+ but can also be CD8+ or CD4-/CD8-), Ki-67 is typically very low at 5% to 10%. Unlike some other intestinal lymphomas, Epstein-Barr encoding region staining for Epstein-Barr virus is usually negative. Although initial reports of this rare entity suggested a low likelihood of transformation to a more aggressive process, transformation to peripheral T-cell lymphoma, not otherwise specific and other aggressive forms has since been documented.[3]

Sources: 3

Health professional · Treatment of Indolent T-Cell Lymphoma of the Gastrointestinal Tract

Treatment Options for Indolent T-Cell Lymphoma of the Gastrointestinal Tract

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Response to multiagent chemotherapy is limited, and many patients can be managed with watchful waiting alone. Limited studies suggest that alterations in the JAK/STAT pathway or genes involved in epigenetic modification could serve as potential therapeutic targets.[4]

Sources: 4

Health professional

Treatment of Hepatosplenic T-Cell Lymphoma

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of peripheral T-cell lymphoma (PTCL) comprising approximately 1% of PTCL. HSTCL often involves young men. HSTCL appears to be localized to the hepatic and splenic sinusoids, with cell surface expression of the gamma delta T-cell receptor.[1-3] Characteristic chromosomal abnormalities such as isochromosome 7q and trisomy 8 are also suggestive of the diagnosis.[4] While in most cases the neoplastic cells express a gamma delta T-cell receptor (hepatosplenic gamma delta T-cell lymphoma), there are reports of alpha beta T-cell receptor expression (hepatosplenic alpha beta T-cell lymphoma).[5] This lymphoma has an extremely poor prognosis and an extremely aggressive clinical course.

Sources: 1 · 3 · 4 · 5

Health professional · Treatment of Hepatosplenic T-Cell Lymphoma

Treatment Options for Hepatosplenic T-Cell Lymphoma

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

HSTCL is treated with induction chemotherapy and stem cell transplant (SCT) consolidation.[3,6]

Sources: 3 · 6

Evidence (induction chemotherapy and SCT consolidation):

A meta-analysis of 118 patients with HSTCL compared CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and CHOP-like induction regimens.[7]

Sources: 7

A meta-analysis of 118 patients with HSTCL compared CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and CHOP-like induction regimens.[7]

Non–CHOP-based regimens (containing cytarabine, etoposide, and/or platinum-based treatment) were associated with improved outcomes, including an overall response rate of 82% versus 52% (P = .006) and a median overall survival (OS) of 36.5 months versus 18 months (P = .00014).

Consolidation with allogeneic SCT was associated with an improved median OS of 33 months, versus 27 months (P = .016) for autologous SCT.[7][Level of evidence C3]

Sources: 7 · Level of evidence C3

The use of ICE (ifosfamide, carboplatin, and etoposide) or IVAC (ifosfamide, etoposide, and high-dose cytarabine) has resulted in improved responses when compared with CHOP in other smaller studies as well.[8][Level of evidence D] Given the inadequate responses to CHOP or CHOP-like regimens, many clinicians are using ICE chemotherapy as front-line induction therapy, followed by consolidative allogeneic SCT for patients achieving a first remission. However, the efficacy of this approach is undetermined.

Sources: 8 · Level of evidence D

Health professional

Treatment of Adult T-Cell Leukemia/Lymphoma

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Adult T-cell leukemia/lymphoma (ATL) is caused by infection with the retrovirus human T-lymphotrophic virus 1 (HTLV1) and is frequently associated with lymphadenopathy, hypercalcemia, circulating leukemic cells, bone and skin involvement, hepatosplenomegaly, a rapidly progressive course, and poor response to combination chemotherapy.[1,2] HTLV1 is endemic to Japan (especially the southern island of Kyushu), central Africa, the Caribbean islands, and some regions of Central and South America, the Middle East, and Australia. This retrovirus is mostly spread by sexual contact or breastfeeding.[3] ATL has been divided into four clinical subtypes:[3]

Sources: 1 · 2 · 3 · 3

Acute (aggressive course with leukemia, with or without extranodal or nodal involvement).

Lymphoma (aggressive course with lymphadenopathy and no leukemia).

Chronic (indolent course with leukemia and lymphadenopathy).

Smoldering (indolent course with only leukemia).

Health professional · Treatment of Adult T-Cell Leukemia/Lymphoma

Treatment Options for Adult T-Cell Leukemia/Lymphoma

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Treatment options for ATL include:

Biological and targeted therapies.

Sources: Biological and targeted therapies

Biological and targeted therapies.

Mogamulizumab.

Sources: Mogamulizumab

Brentuximab vedotin.

Sources: Brentuximab vedotin

Lenalidomide.

Sources: Lenalidomide

Valemetostat.

Sources: Valemetostat

Zidovudine and interferon alfa.

Sources: Zidovudine and interferon alfa

Cytotoxic chemotherapy and allogeneic stem cell transplant (SCT).

Sources: Cytotoxic chemotherapy and allogeneic stem cell transplant (SCT)

Health professional · Treatment of Adult T-Cell Leukemia/Lymphoma / Treatment Options for Adult T-Cell Leukemia/Lymphoma

Biological and targeted therapies

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Health professional · Treatment of Adult T-Cell Leukemia/Lymphoma / Treatment Options for Adult T-Cell Leukemia/Lymphoma / Biological and targeted therapies

Mogamulizumab

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

The anti-CCR4 monoclonal antibody mogamulizumab has a targeted lysis of the ATL clone and also reduces the immunosuppressive Treg population, allowing improvement of cell-mediated immunotherapy.[4] Single-agent phase II trials in patients with ATL showed response rates ranging from 30% to 50%.[5-7][Level of evidence C3] In a phase II study that combined mogamulizumab with combination chemotherapy, 101 patients had an overall response rate of 65% (95% confidence interval [CI], 55%–75%), a median progression-free survival of 7.4 months (95% CI, 5.7–9.1), and a median overall survival (OS) of 16 months (95% CI, 10.3–21.8).[8][Level of evidence C3]

Sources: 4 · 5 · 7 · Level of evidence C3 · 8 · Level of evidence C3

A retrospective review evaluated mogamulizumab combined with both the VCAP-AMP-VECP (vincristine, cyclophosphamide, doxorubicin, prednisone; doxorubicin, ranimustine, prednisone; vindesine, etoposide, carboplatin, prednisone) regimen and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-based regimens versus chemotherapy alone. The review concluded that the 4-year OS rate was 46.3% in the mogamulizumab combination groups, compared with 20.6% in the chemotherapy-alone group.[9][Level of evidence C3] The best results were seen with CHOP-based regimens. Mogamulizumab is available in the United States but has not been approved by the U.S. Food and Drug Administration (FDA) for patients with ATL.

Sources: 9 · Level of evidence C3

Mogamulizumab is often avoided in patients planning allogeneic SCT based on data from Japan that showed an increased risk of severe graft-versus-host disease (GVHD) in patients who received mogamulizumab before allogeneic SCT.[10] The relevance of these findings in other countries and the impact of different GVHD prophylaxis regimens in this setting remains to be determined.

Sources: 10

Health professional · Treatment of Adult T-Cell Leukemia/Lymphoma / Treatment Options for Adult T-Cell Leukemia/Lymphoma / Biological and targeted therapies

Brentuximab vedotin

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Brentuximab vedotin is a monoclonal antibody-drug conjugate directed at CD30 and is a treatment option for patients with ATL whose tumor expresses CD30.[11] Patients with ATL were included in a clinical trial of brentuximab vedotin that mostly involved patients with anaplastic large T-cell lymphoma. A statistical benefit for the very small ATL subgroup could not be established.[11][Level of evidence C3]

Sources: 11 · 11 · Level of evidence C3

Health professional · Treatment of Adult T-Cell Leukemia/Lymphoma / Treatment Options for Adult T-Cell Leukemia/Lymphoma / Biological and targeted therapies

Lenalidomide

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

In a multicenter phase II study (NCT01724177) of 26 patients with relapsed ATL, the overall response rate was 42% (95% CI, 23%–63%) in patients who received the immunomodulatory agent lenalidomide.[12][Level of evidence C3]

Sources: NCT01724177 · 12 · Level of evidence C3

Health professional · Treatment of Adult T-Cell Leukemia/Lymphoma / Treatment Options for Adult T-Cell Leukemia/Lymphoma / Biological and targeted therapies

Valemetostat

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Valemetostat is a selective dual inhibitor of EZH1 and EZH2, which are important histone methyltransferases involved with chromatin folding.[13] A multicenter phase II study (NCT04102150) enrolled 25 patients with relapsed or refractory ATL, 24 of whom had prior therapy with mogamulizumab.[14] With a median follow-up of 6.5 months, the overall response rate was 48% (90% CI, 30.5%–65.9%). There were five complete remissions and seven partial remissions among the heavily pretreated patients.[14][Level of evidence C3] Responses were seen in patients with the acute, lymphoma, and chronic versions of ATL. Although approved for use in Japan, valemetostat is not approved by the FDA for use in the United States.

Sources: 13 · NCT04102150 · 14 · 14 · Level of evidence C3

Health professional · Treatment of Adult T-Cell Leukemia/Lymphoma / Treatment Options for Adult T-Cell Leukemia/Lymphoma / Biological and targeted therapies

Zidovudine and interferon alfa

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

The combination of zidovudine and interferon alfa has activity against ATL, especially among patients with the chronic and smoldering versions of ATL.[15,16] Durable remissions of 8 to 12 months and response rates of 20% to 40% have been reported for patients, some of whom had relapsed disease after prior chemotherapy,[15,16] and some with the acute and lymphoma subtypes of ATL.[17,18]

Sources: 15 · 16 · 15 · 16 · 17 · 18

Health professional · Treatment of Adult T-Cell Leukemia/Lymphoma / Treatment Options for Adult T-Cell Leukemia/Lymphoma

Cytotoxic chemotherapy and allogeneic SCT

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

The acute and lymphoma types of ATL respond poorly to combination cytotoxic chemotherapy and allogeneic SCT, with a median OS under 1 year.[19-21] Less than 10% of patients who received combination therapy were alive after 4 years in one retrospective study.[21] Durable remissions have been reported after allogeneic SCT and even after subsequent donor lymphocyte infusion for relapses after transplant.[22-24][Level of evidence C3] Among 815 patients who underwent allogeneic SCT in two retrospective reviews, the 3-year OS rates were 36% and 26%.[25,26][Level of evidence C1]

Sources: 19 · 21 · 21 · 22 · 24 · Level of evidence C3 · 25 · 26 · Level of evidence C1

The cytotoxic chemotherapy backbone for patients with ATL in the United States and Europe is the CHOP or CHO(E)P regimen (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone). Brentuximab vedotin has been added to CHOP in rare cases when patients express CD30. For the acute and lymphoma versions of ATL, a series of clinical trials in Japan established VCAP-AMP-VECP as the standard first-line treatment.[2,27,28] This regimen has generally not been implemented outside of Asia since a trial comparing VCAP-AMP-VECP versus CHOP-14 did not show statistically improved OS (3-year OS rate, 24% vs. 13%; P = nonsignificant).

Sources: 2 · 27 · 28

Allogeneic SCT is frequently used for patients achieving first or later remission, although results are largely anecdotal.[29,30]

Sources: 29 · 30

Health professional

Treatment of T-Cell Prolymphocytic Leukemia

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Prolymphocytic leukemia (PLL) is a rare form of lymphocytic leukemia characterized by excessive prolymphocytes in the blood with a typical phenotype that is positive for CD19, CD20, and surface-membrane immunoglobulin and negative for CD5.[1] These patients demonstrate splenomegaly and poor response to low-dose or high-dose chemotherapy.[2,3]

Sources: 1 · 2 · 3

Health professional · Treatment of T-Cell Prolymphocytic Leukemia

Treatment Options for T-Cell Prolymphocytic Leukemia

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Cladribine appears to be an active agent (60% complete remission rate) for patients with de novo B-cell PLL.[4][Level of evidence C3] Anecdotal responses have been seen with venetoclax.[5][Level of evidence C3] Alemtuzumab, an anti-CD52 humanized monoclonal antibody, has been used for 76 patients with T-cell PLL after failure of previous chemotherapy (usually pentostatin or cladribine). The response rate was 51% (95% confidence interval, 40%–63%), and the median time to progression was 4.5 months (range, 0.1–45.4).[6][Level of evidence C3] These response rates have been confirmed by other investigators.[7] Patients with chronic lymphocytic leukemia (CLL) and prolymphocytoid transformation maintain the classic CLL phenotype and have a worse prognosis than patients with PLL.

Sources: 4 · Level of evidence C3 · 5 · Level of evidence C3 · 6 · Level of evidence C3 · 7

Health professional

Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Health professional · Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

Treatment Options for Relapsed or Refractory Peripheral T-Cell Lymphoma

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025. Captured 2026-09-09.

Treatment options for relapsed or refractory peripheral T-cell lymphoma include:

Combination chemotherapy.

Combination chemotherapy.

ICE (ifosfamide, carboplatin, and etoposide).[1,2]

Sources: 1 · 2

GEMOX (gemcitabine, oxaliplatin, and dexamethasone).[3]

Sources: 3

DHAP (dexamethasone, high-dose cytarabine, and cisplatin).[4]

Sources: 4

ESHAP (etoposide, methylprednisolone, high-dose cytarabine, and cisplatin).[5,6]

Sources: 5 · 6

Hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone).[7]

Sources: 7

Antibody conjugates.

Antibody conjugates.

Brentuximab vedotin (for CD30-positive patients).

Histone deacetylase inhibitors.

Histone deacetylase inhibitors.

Romidepsin.[8]

Sources: 8

Belinostat.[9,10]

Sources: 9 · 10

Dihydrofolate reductase inhibitors.

Dihydrofolate reductase inhibitors.

Pralatrexate.[11]

Sources: 11

Anti-CD52 monoclonal antibodies.

Anti-CD52 monoclonal antibodies.

Alemtuzumab (only available through a restricted distribution program).

Stem cell transplant.[12-16]

Sources: 12 · 16

Studies

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

NCT00866047 · COMPLETED · phase2

Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin

ClinicalTrials.gov record

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

NCT00939770 · COMPLETED · phase1, phase2

Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Malignant...

ClinicalTrials.gov record

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

NCT01492088 · COMPLETED · phase1, phase2

Relapsed or Refractory Hodgkin Lymphoma, Relapsed or Refractory Anaplastic Large-cell Lymphoma

ClinicalTrials.gov record

A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

NCT01724177 · COMPLETED · phase2

Adult T-Cell Leukemia-Lymphoma

ClinicalTrials.gov record

GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma

NCT02733458 · COMPLETED · na

Extranodal NK-T-Cell Lymphoma, Nasal Type

ClinicalTrials.gov record

A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)

NCT03595657 · COMPLETED · phase2

Extranodal Natural Killer/T-Cell Lymphoma

ClinicalTrials.gov record

Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

NCT04102150 · COMPLETED · phase2

Adult T-cell Leukemia/Lymphoma

ClinicalTrials.gov record

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

NCT00109928 · COMPLETED · phase2

Lymphoma

ClinicalTrials.gov record

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

NCT00211185 · COMPLETED · phase2

Lymphoma, T-Cell, Peripheral

ClinicalTrials.gov record

Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms

NCT00217425 · COMPLETED · phase2

Lymphoma

ClinicalTrials.gov record

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

NCT00290433 · COMPLETED · phase2

Lymphoma

ClinicalTrials.gov record

A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma

NCT00337987 · COMPLETED · phase2

Peripheral T-Cell Lymphoma

ClinicalTrials.gov record

Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL

NCT00355472 · COMPLETED · phase1

Adult T-Cell Leukemia and Lymphoma (ATL), Adult Peripheral T-Cell Lymphoma (PTCL)

ClinicalTrials.gov record

Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

NCT00364923 · COMPLETED · phase2

Peripheral T-cell Lymphoma

ClinicalTrials.gov record

A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

NCT00426764 · COMPLETED · phase2

Peripheral T-cell Lymphoma

ClinicalTrials.gov record

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

NCT00481871 · COMPLETED · phase1, phase2

Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia

ClinicalTrials.gov record

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

NCT00632827 · TERMINATED · phase2

Peripheral T-Cell Lymphoma

ClinicalTrials.gov record

Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma

NCT00865969 · COMPLETED · phase2

Peripheral T-cell Lymphoma

ClinicalTrials.gov record

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

NCT00888927 · COMPLETED · phase1, phase2

Peripheral T-Cell Lymphoma

ClinicalTrials.gov record

Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides

NCT00985140 · TERMINATED · Phase not reported

Mycosis Fungoides, Lymphomas: Non-Hodgkin, Lymphomas: Non-Hodgkin Peripheral T-Cell, Lymphomas: Non-Hodgkin Cutaneous Lymphoma

ClinicalTrials.gov record

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

NCT01336933 · COMPLETED · phase2

Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma

ClinicalTrials.gov record

E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma

NCT01401530 · COMPLETED · phase1

Peripheral T-Cell Lymphoma

ClinicalTrials.gov record

Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

NCT01420679 · TERMINATED · phase3

Peripheral T-cell Lymphoma

ClinicalTrials.gov record

A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)

NCT01456039 · COMPLETED · phase1, phase2

Lymphoma, T-cell, Peripheral

ClinicalTrials.gov record

Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

NCT01466881 · COMPLETED · phase2

Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma, Mature T-Cell and NK-Cell...

ClinicalTrials.gov record

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

NCT01482962 · COMPLETED · phase3

Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma

ClinicalTrials.gov record

Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

NCT01606878 · COMPLETED · phase1

Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Neuroblastoma

ClinicalTrials.gov record

A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

NCT01614197 · COMPLETED · phase1

Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma

ClinicalTrials.gov record

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

NCT01716806 · COMPLETED · phase2

Hodgkin Disease, Peripheral T Cell Lymphoma

ClinicalTrials.gov record

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

NCT01742286 · COMPLETED · phase1

ALK-activated Tumors

ClinicalTrials.gov record

Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients

NCT01822886 · COMPLETED · phase2

Peripheral T-cell Lymphoma

ClinicalTrials.gov record

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

NCT01841021 · TERMINATED · na

Peripheral T-Cell Lymphoma

ClinicalTrials.gov record

A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

NCT01950364 · COMPLETED · phase1

Hodgkin Lymphoma, Anaplastic Large-cell Lymphoma

ClinicalTrials.gov record

Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas

NCT02158975 · COMPLETED · phase2

Lymphoma, T-Cell

ClinicalTrials.gov record

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

NCT02264613 · COMPLETED · phase1, phase2

Solid Tumor, Lymphoma, Peripheral T-Cell Lymphoma

ClinicalTrials.gov record

Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy

NCT02464228 · COMPLETED · phase2

Relapsed or Refractory Peripheral T-Cell Lymphoma

ClinicalTrials.gov record

Ceritinib Rare Indications Study in ALK+ Tumors

NCT02465528 · TERMINATED · phase2

Tumors With Aberrations in ALK, Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumor, Glioblastoma

ClinicalTrials.gov record

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

NCT02561273 · COMPLETED · phase1, phase2

Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified,...

ClinicalTrials.gov record

A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT02653976 · COMPLETED · phase2

Peripheral T-Cell Lymphoma

ClinicalTrials.gov record

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT02953652 · COMPLETED · phase2

Peripheral T-Cell Lymphoma (PTCL)

ClinicalTrials.gov record

Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma

NCT03046953 · COMPLETED · phase2

T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory

ClinicalTrials.gov record

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

NCT03075553 · TERMINATED · phase2

Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma, HTLV-1 Infection, NK-Cell Lymphoma, Unclassifiable, Primary Systemic Anaplastic Large Cell...

ClinicalTrials.gov record

A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL

NCT03349333 · COMPLETED · phase3

Refractory Peripheral T-Cell Lymphoma, Relapsed T-Cell Lymphoma

ClinicalTrials.gov record

A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT03372057 · COMPLETED · phase2

Peripheral T-cell Lymphoma

ClinicalTrials.gov record

CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

NCT03542266 · COMPLETED · phase2

Previously Untreated Peripheral T-cell Lymphoma

ClinicalTrials.gov record

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

NCT03547700 · TERMINATED · phase1, phase2

Lymphoma, T-Cell, Peripheral

ClinicalTrials.gov record

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

NCT03586999 · COMPLETED · phase1, phase2

Peripheral T Cell Lymphoma

ClinicalTrials.gov record

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

NCT03905135 · COMPLETED · phase1

Peripheral T-cell Lymphoma NOS, Mycosis Fungoides, Sezary Syndrome, Anaplastic Large Cell Lymphoma

ClinicalTrials.gov record

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

NCT03927105 · COMPLETED · phase2

Peripheral T Cell Lymphoma

ClinicalTrials.gov record

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

NCT03947255 · TERMINATED · phase2

Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma

ClinicalTrials.gov record

Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

NCT04101331 · COMPLETED · phase2

Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides

ClinicalTrials.gov record

Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

NCT04105010 · COMPLETED · phase1, phase2

Relapsed or Refractory Peripheral T Cell Lymphoma

ClinicalTrials.gov record

Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"

NCT04213209 · COMPLETED · Phase not reported

Peripheral T Cell Lymphoma, Pediatric Hodgkin Lymphoma

ClinicalTrials.gov record

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

NCT04569032 · COMPLETED · phase2

Peripheral T-cell Lymphoma

ClinicalTrials.gov record

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

NCT04703192 · ACTIVE NOT RECRUITING · phase2

Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma

ClinicalTrials.gov record

AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL

NCT05140382 · COMPLETED · phase2

Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma

ClinicalTrials.gov record

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

NCT05673785 · ACTIVE NOT RECRUITING · phase2

Lymphoma

ClinicalTrials.gov record

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

NCT05883449 · TERMINATED · phase2

Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma

ClinicalTrials.gov record

Disease and treatment settings

Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma

Disease and treatment setting

Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma

Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma

Disease and treatment setting

Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma

Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma

Disease and treatment setting

Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma

Peripheral T-Cell Non-Hodgkin Lymphoma

Disease and treatment setting

Peripheral T-Cell Non-Hodgkin Lymphoma

refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Disease and treatment setting

Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

Systemic Anaplastic Large Cell Lymphoma, ALK-Negative

Disease and treatment setting

Systemic Anaplastic Large Cell Lymphoma, ALK-Negative

Drug labels

Beleodaq

Label date 2025-04-07

Beleodaq is indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response [ see...

DailyMed label

Folotyn

Label date 2024-09-26

FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on overall response rate [ see Clinical Studies (14) ] ....

DailyMed label

Pralatrexate

Label date 2022-11-15

Pralatrexate injection is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on overall response rate [see Clinical Studies...

DailyMed label